ACRV vs. PRQR, BYSI, IMMP, VTVT, ASMB, AVRO, SLDB, STTK, CRBP, and CELC
Should you be buying Acrivon Therapeutics stock or one of its competitors? The main competitors of Acrivon Therapeutics include ProQR Therapeutics (PRQR), BeyondSpring (BYSI), Immutep (IMMP), vTv Therapeutics (VTVT), Assembly Biosciences (ASMB), AVROBIO (AVRO), Solid Biosciences (SLDB), Shattuck Labs (STTK), Corbus Pharmaceuticals (CRBP), and Celcuity (CELC). These companies are all part of the "medical" sector.
Acrivon Therapeutics (NASDAQ:ACRV) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends, community ranking and earnings.
Acrivon Therapeutics currently has a consensus price target of $22.88, indicating a potential upside of 196.31%. ProQR Therapeutics has a consensus price target of $3.38, indicating a potential upside of 83.42%. Given Acrivon Therapeutics' higher probable upside, equities research analysts clearly believe Acrivon Therapeutics is more favorable than ProQR Therapeutics.
Acrivon Therapeutics has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500. Comparatively, ProQR Therapeutics has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500.
Acrivon Therapeutics has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -260.75%. Acrivon Therapeutics' return on equity of -49.65% beat ProQR Therapeutics' return on equity.
71.6% of Acrivon Therapeutics shares are owned by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are owned by institutional investors. 8.5% of Acrivon Therapeutics shares are owned by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
ProQR Therapeutics received 301 more outperform votes than Acrivon Therapeutics when rated by MarketBeat users. However, 96.15% of users gave Acrivon Therapeutics an outperform vote while only 61.86% of users gave ProQR Therapeutics an outperform vote.
ProQR Therapeutics has higher revenue and earnings than Acrivon Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, ProQR Therapeutics had 1 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 3 mentions for ProQR Therapeutics and 2 mentions for Acrivon Therapeutics. ProQR Therapeutics' average media sentiment score of 1.45 beat Acrivon Therapeutics' score of 1.15 indicating that ProQR Therapeutics is being referred to more favorably in the news media.
Summary
Acrivon Therapeutics beats ProQR Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Acrivon Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acrivon Therapeutics Competitors List
Related Companies and Tools
